The present simulations suggest, however, that any change between a response above and below the immunological threshold—as might occur in patients with cancer due to stress etc. [31]—could lead to periods of tumor growth and regression, highlighting the need not to suspend G-CSF treatment too early.The risk of possible side effects when maintaining a level of peritumoral inflammation above the proposed immunological threshold would appear acceptable in the treatment of cancer. The gene discussed is CSF3; the disease is neoplasm.